Tauns Laboratories (TSE:197A) Long-Term Debt: 円12,868 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:197A Tauns Laboratories Inc TSE:197A
15 GF Score
Price 円468.00
! 6 Warning Signs
View Full Analysis

What is Tauns Laboratories Long-Term Debt?

Tauns Laboratories TSE:197A 15 Long-Term Debt is 円12,868 Mil as of Dec. 2025. GuruFocus rates TSE:197A with a GF Score™ of 15/100. The stock has 6 warning signs investors should review.

Tauns Laboratories's Long-Term Debt for the quarter that ended in Dec. 2025 was 円12,868 Mil.

Tauns Laboratories's quarterly Long-Term Debt increased from Jun. 2025 (円8,809 Mil) to Sep. 2025 (円13,314 Mil) but then declined from Sep. 2025 (円13,314 Mil) to Dec. 2025 (円12,868 Mil).

Tauns Laboratories's annual Long-Term Debt increased from Jun. 2023 (円2,236 Mil) to Jun. 2024 (円4,307 Mil) and increased from Jun. 2024 (円4,307 Mil) to Jun. 2025 (円8,809 Mil).

Tauns Laboratories  (TSE:197A) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Tauns Laboratories Long-Term Debt Related Terms

Tauns Laboratories Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Tauns Laboratories's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tauns Laboratories Long-Term Debt Chart

Tauns Laboratories Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Long-Term Debt
2,968.00 2,236.00 4,307.00 8,809.08

Tauns Laboratories Quarterly Data
Jun22 Jun23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,300.00 8,809.08 13,313.88 12,868.09 12,422.30
TSE:197A
15GF Score
Tauns Laboratories Inc TSE:197A
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of 円12,868 Mil mean?
Tauns Laboratories (TSE:197A) has a Long-Term Debt of 円12,868 Mil as of Dec. 2025.
Is Tauns Laboratories' Long-Term Debt too high?
Tauns Laboratories' current Long-Term Debt is 円12,868 Mil. Overall, Tauns Laboratories has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Tauns Laboratories' Long-Term Debt compare to ISRG and BDX?
Tauns Laboratories' Long-Term Debt of 円12,868 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Tauns Laboratories's current Long-Term Debt is 円12,868 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tauns Laboratories stock overvalued right now?
Tauns Laboratories (TSE:197A) has a current Long-Term Debt of 円12,868 Mil. The current Long-Term Debt is 円12,868 Mil. Tauns Laboratories' overall GF Score™ is 15/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Tauns Laboratories (TSE:197A), the current Long-Term Debt is 円12,868 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tauns Laboratories Business Description

Address 761-1 Kamishima Izunokuni-shi, Shizuoka, JPN, 410-2325
Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.
15GF Score

Get the complete analysis for TSE:197A

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円468.00
Price